MGCD 290

Drug Profile

MGCD 290

Alternative Names: Antifungal Hos2 histone deacetylase (HDAC) enzyme inhibitor (MGCD290); MG-3290; MGCD-290

Latest Information Update: 28 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MethylGene
  • Class Antifungals; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Mycoses; Vulvovaginal candidiasis

Most Recent Events

  • 28 Mar 2014 MGCD 290 is available for licensing in World as of 28 Mar 2014.
  • 31 Dec 2013 Suspended - Phase-I for Mycoses (in volunteers) in Canada (PO)
  • 31 Dec 2013 Suspended - Phase-II for Vulvovaginal candidiasis (combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top